Related Experiment Video

Updated: Jul 8, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Novel checkpoint 1 inhibitors

Michelle Prudhomme1

  • 1Laboratoire SEESIB, Université Blaise Pascal, UMR 6504 du CNRS, 63177 Aubière, France. Michelle.PRUDHOMME@univ-bpclermont.fr

Recent Patents on Anti-Cancer Drug Discovery
|January 29, 2008
PubMed

Insights

Checkpoint 1 kinase (Chk1) inhibitors combined with DNA damaging agents selectively induce lethal mitosis in cancer cells lacking the G1 checkpoint. This strategy enhances antitumor efficacy by preventing DNA repair.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Drug Discovery

Background:

  • Cell cycle checkpoints, including G1 and G2, are crucial for DNA repair following damage.
  • The G1 checkpoint relies on p53 protein, which is frequently mutated in human tumors, rendering these cells deficient in G1 checkpoint control.
  • Cancer cells with p53 mutations rely on a weakened G2 checkpoint for DNA repair, presenting a therapeutic vulnerability.

Purpose of the Study:

  • To review novel Chk1 inhibitors for cancer therapy.
  • To evaluate the efficacy of combining Chk1 inhibitors with DNA damaging agents.
  • To explore the potential of targeting the G2 checkpoint in p53-mutated cancers.

Main Methods:

  • Review of recent patents detailing Chk1 inhibitor chemical structures.
  • Assessment of Chk1 inhibitory activity.
  • Evaluation of combined treatment effects on tumor cells.
  • Analysis of in vivo results from animal models.

Main Results:

  • Identification and characterization of novel Chk1 inhibitors.
  • Demonstration of enhanced tumor cell death when Chk1 inhibitors are combined with DNA damaging agents.
  • Positive outcomes in preclinical animal models.

Conclusions:

  • Chk1 inhibitors represent a promising therapeutic strategy to enhance DNA damaging agent efficacy.
  • Targeting the G2 checkpoint offers a selective approach to eliminate cancer cells with p53 mutations.
  • Further development of Chk1 inhibitors is warranted for cancer treatment.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Inhibitors of Virion Maturation and Assembly01:19

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...